Fluoropyrimidine

DRUG10 trials

Conditions

Advanced Esophageal CancerAdvanced Gastric CancerAdvanced Gastroesophageal Junction AdenocarcinomaAutoimmune DiseaseColon Cancer MetastaticColorectal CancerCrohn DiseaseDermatomyositis

Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

RecruitingNCT03816345

National Cancer Institute (NCI)Autoimmune Disease, Crohn Disease, Dermatomyositis +11

Start: 2019-07-16End: 2028-03-30Target: 300Updated: 2026-10-05

A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT07818018

Memorial Sloan Kettering Cancer CenterAdvanced Esophageal Cancer, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma +5

Start: 2026-09-04End: 2029-09-04Target: 30Updated: 2026-09-14

Phase 2

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

TerminatedNCT00033306

University of Alabama at BirminghamColorectal Cancer

Start: 2002-02-28End: 2005-07-31Updated: 2013-08-05

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

CompletedNCT00399750

SanofiColorectal Cancer

Start: 2002-11-30End: 2005-06-30Target: 373Updated: 2009-10-15

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

Enrolling by invitationNCT06648785

University of Vermont Medical CenterGI Cancers

Start: 2024-10-21End: 2026-11-01Target: 20Updated: 2026-02-05

Phase 3

Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis

NCT03023436

Nanfang Hospital, Southern Medical UniversityStomach Neoplasm

Start: 2016-01-31End: 2022-06-30Target: 220Updated: 2019-09-13

A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer

Active, not recruitingNCT04188145

Centre Hospitalier Universitaire DijonMetastatic Colorectal Cancer

Start: 2020-01-27End: 2029-09-01Target: 400Updated: 2026-07-16

A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma

Active, not recruitingNCT04257461

Belgian Group of Digestive OncologySmall Bowel Adenocarcinoma

Start: 2020-02-20End: 2025-12-31Target: 30Updated: 2025-02-06

Unknown Phase

Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study

Enrolling by invitationNCT04260269

Helsinki University Central HospitalSolid Tumor

Start: 2018-06-01End: 2027-12-31Target: 200Updated: 2024-12-12

Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC

Active, not recruitingNCT07494578

Fondazione Policlinico Universitario Agostino Gemelli IRCCSColon Cancer Metastatic

Start: 2025-07-01End: 2027-08-01Target: 300Updated: 2026-03-27

2022-03-3019 citations

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.

2021-06-2334 citations

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology2021-05-2029 citations

Abstract CT249: A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)

Cancer Research2020-08-15

A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

Journal of Clinical Oncology2020-05-206 citations

Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors.

Journal of Clinical Oncology2020-05-202 citations